MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy

MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most studies have focused on MYC translocations but there is little information regarding the impact of numerical alterations and protein expression. We analyzed the genetic alterations and protein expression of M...

ver descrição completa

Detalhes bibliográficos
Autores: Valera Barros, Alexandra, López Guillermo, Armando, Cardesa García, Antonio, Climent, Fina, González Barca, Eva, Mercadal, Santiago, Espinosa, Iñigo, Novelli, Silvana, Briones, Javier, Mate, José L., Salamero, Olga, Sancho, Juan Manuel, Arenillas Rocha, Leonor, Serrano, Sergi, Erill, Nadina, Martínez, Daniel, Castillo, Paola, Rovira, Jordina, Martínez, Antonio, Campo Güerri, Elias, Colomo Saperas, Lluís
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2013
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/68680
Acesso em linha:https://hdl.handle.net/2445/68680
Access Level:acceso abierto
Palavra-chave:Limfomes
Immunoteràpia
Oncogens
Pronòstic mèdic
Lymphomas
Immunotheraphy
Oncogenes
Prognosis
id ES_f680d6a02f697d57915f962a25ddac0f
oai_identifier_str oai:recercat.cat:2445/68680
network_acronym_str ES
network_name_str España
repository_id_str
spelling MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapyValera Barros, AlexandraLópez Guillermo, ArmandoCardesa García, AntonioCliment, FinaGonzález Barca, EvaMercadal, SantiagoEspinosa, IñigoNovelli, SilvanaBriones, JavierMate, José L.Salamero, OlgaSancho, Juan ManuelArenillas Rocha, LeonorSerrano, SergiErill, NadinaMartínez, DanielCastillo, PaolaRovira, JordinaMartínez, AntonioCampo Güerri, EliasColomo Saperas, LluísLimfomesImmunoteràpiaOncogensPronòstic mèdicLymphomasImmunotheraphyOncogenesPrognosisMYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most studies have focused on MYC translocations but there is little information regarding the impact of numerical alterations and protein expression. We analyzed the genetic alterations and protein expression of MYC, BCL2, BCL6, and MALT1 in 219 cases of diffuse large B-cell lymphoma. MYC rearrangement occurred as the sole abnormality (MYC single-hit) in 3% of cases, MYC and concurrent BCL2 and/or BCL6 rearrangements (MYC double/triple-hit) in 4%, MYC amplifications in 2% and MYC gains in 19%. MYC single-hit, MYC double/triple-hit and MYC amplifications, but not MYC gains or other gene rearrangements, were associated with unfavorable progression-free survival and overall survival. MYC protein expression, evaluated using computerized image analysis, captured the unfavorable prognosis of MYC translocations/amplifications and identified an additional subset of patients without gene alterations but with similar poor prognosis. Patients with tumors expressing both MYC/BCL2 had the worst prognosis, whereas those with double-negative tumors had the best outcome. High MYC expression was associated with shorter overall survival irrespectively of the International Prognostic Index and BCL2 expression. In conclusion, MYC protein expression identifies a subset of diffuse large B-cell lymphoma with very poor prognosis independently of gene alterations and other prognostic parameters.Ferrata Storti Foundation2016201620132016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9 p.application/pdfhttps://hdl.handle.net/2445/68680Articles publicats en revistes (Fonaments Clínics)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: http://dx.doi.org/10.3324/haematol.2013.086173Haematologica, 2013, vol. 98, num. 10, p. 1554-1562http://dx.doi.org/10.3324/haematol.2013.086173(c) Ferrata Storti Foundation, 2013info:eu-repo/semantics/openAccessoai:recercat.cat:2445/686802026-05-29T05:05:01Z
dc.title.none.fl_str_mv MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
title MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
spellingShingle MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
Valera Barros, Alexandra
Limfomes
Immunoteràpia
Oncogens
Pronòstic mèdic
Lymphomas
Immunotheraphy
Oncogenes
Prognosis
title_short MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
title_full MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
title_fullStr MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
title_full_unstemmed MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
title_sort MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
dc.creator.none.fl_str_mv Valera Barros, Alexandra
López Guillermo, Armando
Cardesa García, Antonio
Climent, Fina
González Barca, Eva
Mercadal, Santiago
Espinosa, Iñigo
Novelli, Silvana
Briones, Javier
Mate, José L.
Salamero, Olga
Sancho, Juan Manuel
Arenillas Rocha, Leonor
Serrano, Sergi
Erill, Nadina
Martínez, Daniel
Castillo, Paola
Rovira, Jordina
Martínez, Antonio
Campo Güerri, Elias
Colomo Saperas, Lluís
author Valera Barros, Alexandra
author_facet Valera Barros, Alexandra
López Guillermo, Armando
Cardesa García, Antonio
Climent, Fina
González Barca, Eva
Mercadal, Santiago
Espinosa, Iñigo
Novelli, Silvana
Briones, Javier
Mate, José L.
Salamero, Olga
Sancho, Juan Manuel
Arenillas Rocha, Leonor
Serrano, Sergi
Erill, Nadina
Martínez, Daniel
Castillo, Paola
Rovira, Jordina
Martínez, Antonio
Campo Güerri, Elias
Colomo Saperas, Lluís
author_role author
author2 López Guillermo, Armando
Cardesa García, Antonio
Climent, Fina
González Barca, Eva
Mercadal, Santiago
Espinosa, Iñigo
Novelli, Silvana
Briones, Javier
Mate, José L.
Salamero, Olga
Sancho, Juan Manuel
Arenillas Rocha, Leonor
Serrano, Sergi
Erill, Nadina
Martínez, Daniel
Castillo, Paola
Rovira, Jordina
Martínez, Antonio
Campo Güerri, Elias
Colomo Saperas, Lluís
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Limfomes
Immunoteràpia
Oncogens
Pronòstic mèdic
Lymphomas
Immunotheraphy
Oncogenes
Prognosis
topic Limfomes
Immunoteràpia
Oncogens
Pronòstic mèdic
Lymphomas
Immunotheraphy
Oncogenes
Prognosis
description MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most studies have focused on MYC translocations but there is little information regarding the impact of numerical alterations and protein expression. We analyzed the genetic alterations and protein expression of MYC, BCL2, BCL6, and MALT1 in 219 cases of diffuse large B-cell lymphoma. MYC rearrangement occurred as the sole abnormality (MYC single-hit) in 3% of cases, MYC and concurrent BCL2 and/or BCL6 rearrangements (MYC double/triple-hit) in 4%, MYC amplifications in 2% and MYC gains in 19%. MYC single-hit, MYC double/triple-hit and MYC amplifications, but not MYC gains or other gene rearrangements, were associated with unfavorable progression-free survival and overall survival. MYC protein expression, evaluated using computerized image analysis, captured the unfavorable prognosis of MYC translocations/amplifications and identified an additional subset of patients without gene alterations but with similar poor prognosis. Patients with tumors expressing both MYC/BCL2 had the worst prognosis, whereas those with double-negative tumors had the best outcome. High MYC expression was associated with shorter overall survival irrespectively of the International Prognostic Index and BCL2 expression. In conclusion, MYC protein expression identifies a subset of diffuse large B-cell lymphoma with very poor prognosis independently of gene alterations and other prognostic parameters.
publishDate 2013
dc.date.none.fl_str_mv 2013
2016
2016
2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/68680
url https://hdl.handle.net/2445/68680
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: http://dx.doi.org/10.3324/haematol.2013.086173
Haematologica, 2013, vol. 98, num. 10, p. 1554-1562
http://dx.doi.org/10.3324/haematol.2013.086173
dc.rights.none.fl_str_mv (c) Ferrata Storti Foundation, 2013
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Ferrata Storti Foundation, 2013
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
dc.publisher.none.fl_str_mv Ferrata Storti Foundation
publisher.none.fl_str_mv Ferrata Storti Foundation
dc.source.none.fl_str_mv Articles publicats en revistes (Fonaments Clínics)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424769164640256
score 15.811543